Harmony Biosciences/$HRMY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
- Ticker
- $HRMY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 293
- Headquarters
- Plymouth Meeting, United States
- Website
- www.harmonybiosciences.com
HRMY Metrics
BasicAdvanced
$2.3B
12.54
$3.09
0.92
-
Price and volume
Market cap
$2.3B
Beta
0.92
52-week high
$43.49
52-week low
$25.90
Average daily volume
977K
Financial strength
Current ratio
3.479
Quick ratio
3.327
Long term debt to equity
0.139
Total debt to equity
0.16
Interest coverage (TTM)
17.12%
Profitability
EBITDA (TTM)
255.987
Gross margin (TTM)
75.42%
Net profit margin (TTM)
18.88%
Operating margin (TTM)
24.03%
Effective tax rate (TTM)
24.85%
Revenue per employee (TTM)
$3,280,000
Management effectiveness
Return on assets (TTM)
11.62%
Return on equity (TTM)
20.46%
Valuation
Price to earnings (TTM)
12.54
Price to revenue (TTM)
2.331
Price to book
2.25
Price to tangible book (TTM)
2.44
Price to free cash flow (TTM)
7.37
Free cash flow yield (TTM)
13.57%
Free cash flow per share (TTM)
5.259
Growth
Revenue change (TTM)
24.25%
Earnings per share change (TTM)
-0.15%
3-year revenue growth (CAGR)
24.38%
3-year earnings per share growth (CAGR)
-1.92%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
Analyst projections of the future price of Harmony Biosciences stock.
Bulls say / Bears say
WAKIX sales rose 30% year on year to $261.3 million in Q2, and Harmony maintained its $1.0–$1.04 billion revenue forecast for 2026. Continued patient growth supports the case that the core franchise still has room to expand. (GlobeNewswire)
The FDA approved WAKIX for cataplexy in children in February, giving Harmony a new patient group to serve. The company said it began promoting the expanded indication after approval. (Harmony Biosciences)
EPX-100 offers a potential growth avenue beyond sleep disorders: preliminary open-label data in Dravet syndrome showed a median 49.2% reduction in motor seizures after six months. The candidate is also being tested in two ongoing Phase 3 studies, though the early data are not proof of efficacy. (Neurology, GlobeNewswire)
Harmony remains heavily reliant on WAKIX, its only commercial product, so any loss of demand or access could hit revenue with little offset from other marketed drugs. Q2 filings show that WAKIX remains the sole commercial product. (StockTitan)
WAKIX’s patent protection is still being contested: AET and Sandoz remain in litigation, and Harmony has brought another patent case against them. An adverse outcome could bring generic competition sooner than the company expects. (GlobeNewswire, Bloomberg Law)
WAKIX product costs rose 66% in Q2, faster than the 30% increase in revenue, as new royalties lifted costs. If that pattern persists, sales growth may translate less effectively into profit. (TradingKey)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
Upcoming events
No upcoming events
HRMY News
AllArticlesVideos
Funds containing HRMY
AllUSDEURGBP
Fund name | Fund size | $HRMY weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.19% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.19% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.19% |
iShares Ageing Population$AGED | $953M | 0.18% |
iShares Ageing Population£AGES | $953M | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.